Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MLSSNASDAQ:NRXSNYSE:NSPRNASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLSSMilestone Scientific$0.88-1.1%$0.94$0.58▼$1.39$69.06M0.9129,701 shs60,574 shsNRXSNeurAxis$2.29-0.4%$2.33$1.33▼$6.20$16.53M3.34413,961 shs85,172 shsNSPRInspireMD$2.32-7.2%$2.51$2.07▼$3.80$71.07M0.5939,491 shs125,380 shsTELATELA Bio$1.70-8.1%$1.21$0.86▼$5.60$67.24M0.78230,304 shs166,026 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLSSMilestone Scientific-0.01%-1.32%-2.19%-3.80%+27.16%NRXSNeurAxis-7.63%-11.54%0.00%+6.48%-21.50%NSPRInspireMD+2.04%0.00%+2.88%-10.71%-4.94%TELATELA Bio-1.07%-5.13%+88.78%-21.28%-67.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMLSSMilestone Scientific2.2725 of 5 stars3.53.00.00.01.62.50.0NRXSNeurAxis0.9496 of 5 stars0.03.00.00.02.23.30.0NSPRInspireMD2.0373 of 5 stars3.52.00.00.00.62.50.6TELATELA Bio2.4463 of 5 stars3.43.00.00.02.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMLSSMilestone Scientific 3.00Buy$1.2542.05% UpsideNRXSNeurAxis 0.00N/AN/AN/ANSPRInspireMD 3.00Buy$4.5093.97% UpsideTELATELA Bio 2.75Moderate Buy$7.25326.47% UpsideCurrent Analyst Ratings BreakdownLatest NRXS, TELA, NSPR, and MLSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.003/21/2025TELATELA BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $7.003/21/2025TELATELA BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$5.00 ➝ $2.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMLSSMilestone Scientific$8.61M8.02N/AN/A$0.11 per share8.00NRXSNeurAxis$2.93M5.63N/AN/A($0.27) per share-8.48NSPRInspireMD$7.03M10.11N/AN/A$1.83 per share1.27TELATELA Bio$71.22M0.94N/AN/A$0.77 per share2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMLSSMilestone Scientific-$6.93M-$0.07N/A∞N/A-52.01%-60.26%-40.23%N/ANRXSNeurAxis-$14.63M-$1.19N/A∞N/A-492.76%N/A-641.25%N/ANSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ATELATELA Bio-$46.66M-$1.41N/AN/AN/A-60.49%-556.18%-63.13%8/11/2025 (Estimated)Latest NRXS, TELA, NSPR, and MLSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TELATELA Bio-$0.21-$0.25-$0.04-$0.25$17.35 million$18.52 million3/20/2025Q4 2024TELATELA Bio-$0.24-$0.23+$0.01-$0.23$23.17 million$17.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMLSSMilestone ScientificN/AN/AN/AN/AN/ANRXSNeurAxisN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMLSSMilestone ScientificN/A2.851.86NRXSNeurAxisN/A0.240.23NSPRInspireMDN/A6.396.05TELATELA Bio14.222.621.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMLSSMilestone Scientific5.79%NRXSNeurAxis11.77%NSPRInspireMD44.78%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipMLSSMilestone Scientific24.75%NRXSNeurAxis26.40%NSPRInspireMD34.06%TELATELA Bio4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMLSSMilestone Scientific3078.48 million58.61 millionOptionableNRXSNeurAxis197.22 million6.09 millionNot OptionableNSPRInspireMD5030.64 million18.33 millionOptionableTELATELA Bio12039.56 million37.03 millionOptionableNRXS, TELA, NSPR, and MLSS HeadlinesRecent News About These CompaniesTELA Bio Welcomes Jim Hagen with Strategic Equity GrantJune 9, 2025 | msn.comTELA Bio (NASDAQ:TELA) Upgraded at Wall Street ZenJune 9, 2025 | americanbankingnews.comTELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2025 | finanznachrichten.deTELA Bio (NASDAQ:TELA) Stock Rating Upgraded by Wall Street ZenJune 7, 2025 | marketbeat.comTELA Bio, Inc. Grants Inducement Equity Awards to New Senior Vice President Jim HagenJune 6, 2025 | quiverquant.comTELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 5, 2025 | tmcnet.comTELA Bio, Inc. (NASDAQ:TELA) Short Interest Down 13.6% in MayJune 4, 2025 | marketbeat.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 3, 2025 | globenewswire.comTELA Bio Names Jeffrey Blizard as President to Drive Strategic GrowthJune 3, 2025 | msn.comTELA Bio Appoints Jeffrey Blizard as President to Drive Growth and InnovationJune 2, 2025 | quiverquant.comTELA Bio Appoints Jeffrey Blizard as PresidentJune 2, 2025 | globenewswire.comTELA Bio to Present at the 2025 Jefferies Global Healthcare ConferenceMay 25, 2025 | msn.comTELA Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 22, 2025 | globenewswire.comPiper Sandler Sticks to Their Hold Rating for TELA Bio (TELA)May 22, 2025 | theglobeandmail.comTELA Bio Announces Inducement Grants to New Hires with 4-Year Vesting PlanMay 12, 2025 | msn.comTELA Bio Reports Q1 2025 Growth and Product ExpansionMay 12, 2025 | msn.comTELA Bio, Inc. (TELA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comEarnings call transcript: Tela Bio Q1 2025 revenue miss, stock rises 9%May 10, 2025 | uk.investing.comTELA Bio Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finance.yahoo.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRXS, TELA, NSPR, and MLSS Company DescriptionsMilestone Scientific NYSE:MLSS$0.88 -0.01 (-1.13%) Closing price 04:00 PM EasternExtended Trading$0.88 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.NeurAxis NASDAQ:NRXS$2.28 -0.03 (-1.09%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.InspireMD NYSE:NSPR$2.32 -0.18 (-7.20%) Closing price 03:59 PM EasternExtended Trading$2.37 +0.05 (+1.94%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.TELA Bio NASDAQ:TELA$1.70 -0.15 (-8.11%) Closing price 04:00 PM EasternExtended Trading$1.71 +0.01 (+0.59%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
